Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia

In X‐linked hypophosphatemia (XLH), serum fibroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH](2)D) concentrati...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Pharmacol
Главные авторы: Zhang, Xiaoping, Imel, Erik A., Ruppe, Mary D., Weber, Thomas J., Klausner, Mark A., Ito, Takahiro, Vergeire, Maria, Humphrey, Jeffrey, Glorieux, Francis H., Portale, Anthony A., Insogna, Karl, Carpenter, Thomas O., Peacock, Munro
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2015
Предметы:
Pharmacokinetics/Pharmacodynamics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5042055/
https://ncbi.nlm.nih.gov/pubmed/26073451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.570
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы